Literature DB >> 17538805

Short-duration topical treatment of tinea pedis using terbinafine emulsion gel: results of a dose-ranging clinical trial.

Ian G James1, Yolanda Loria-Kanza, Thomas C Jones.   

Abstract

BACKGROUND: In the treatment of tinea pedis, current terbinafine formulations are applied once or twice daily for 7 days. A terbinafine emulsion gel formulation has been developed to provide a 5-day treatment course for tinea pedis.
OBJECTIVE: To determine the lowest effective concentration of terbinafine (1% or 3%) emulsion gel applied once daily for 5 days for the treatment of tinea pedis.
METHODS: This double-blind, placebo-controlled study evaluated the efficacy of 1% and 3% terbinafine gel for 5 days in 84 outpatients with tinea pedis. The primary efficacy endpoint was the percentage of patients with effective treatment (negative microscopy and culture with only mild erythema/desquamation/pruritus [total score<or=2]) at study endpoint (last post-baseline observation up to and including week 6).
RESULTS: Efficacy rates with terbinafine 1% and 3% emulsion gel were significantly higher than with placebo (86% and 68% vs 11%, respectively; p<0.001). Similarly, mycological cure rates were significantly greater with terbinafine 1% and 3% gel (97% and 89%, respectively) than with placebo (22%; p<0.001).
CONCLUSIONS: Terbinafine 1% emulsion gel used once daily for 5 days was the lowest effective concentration, and was significantly superior to placebo. Both concentrations were effective and safe, providing convenient, short-duration treatment of tinea pedis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17538805     DOI: 10.1080/09546630701247971

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  4 in total

Review 1.  Athlete's foot.

Authors:  Fay Crawford
Journal:  BMJ Clin Evid       Date:  2009-07-20

Review 2.  [Topical terbinafine. Reduction of duration of therapy for tinea pedis].

Authors:  M-H Schmid-Wendtner; H Korting
Journal:  Hautarzt       Date:  2008-12       Impact factor: 0.751

3.  Update on terbinafine with a focus on dermatophytoses.

Authors:  Jason G Newland; Susan M Abdel-Rahman
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-04-21

4.  Film-Forming Systems for the Delivery of DNDI-0690 to Treat Cutaneous Leishmaniasis.

Authors:  Katrien Van Bocxlaer; Kerri-Nicola McArthur; Andy Harris; Mo Alavijeh; Stéphanie Braillard; Charles E Mowbray; Simon L Croft
Journal:  Pharmaceutics       Date:  2021-04-08       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.